Provencio and colleagues reported the exploratory efficacy outcomes and safety results from the CheckMate 77T phase 3 trial in patients with stage III resectable non-small-cell lung cancer. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback